Background
==========

Benign prostatic hyperplasia (BPH) is a common urological disorder in men. Its prevalence increases with age and may affect 3 of 4 men in their sixties \[[@B1]-[@B3]\]. BPH may cause gradual obstruction to the bladder outflow, leading to progressive severity in lower urinary tract symptoms such as frequency, urgency, nocturia, incomplete voiding and weak urinary stream.

Residual urine in the bladder in patients with BPH surely increases the contact time between urinary excreted carcinogens and the urothelium. Therefore, theoretically, patients with BPH may have an increased risk of bladder cancer. An animal study conducted in female Wistar rats supported such a hypothesis. Matsumoto et al. found that surgically induced partial bladder outlet obstruction resulted in a greater incidence of bladder cancer induced by the carcinogen n-butyl-n-butanol nitrosamine \[[@B4]\].

Human studies investigating the link between BPH and bladder cancer are still sparse. Two early case--control studies suggested an increased risk \[[@B5],[@B6]\]. A recent cohort study recruiting 79280 Swedish men hospitalized for BPH from 1964 to 1983 and following the patients until 1989 concluded that the overall risk of bladder cancer was not increased with BPH, but patients who underwent transurethral resection of the prostate had a significantly 47% higher risk \[[@B7]\].

On the other hand, diabetes may affect the lower urinary tract symptoms/functions \[[@B8]-[@B13]\], and patients with type 2 diabetes may have a higher risk of BPH \[[@B3],[@B10],[@B12],[@B14]-[@B17]\]. A study estimated that men with higher fasting glucose (\>110 mg/dl vs. 110 mg/dl or less) or with a diagnosis of diabetes may have a significantly 3-fold and 2.3-fold higher risk of BPH, respectively \[[@B14]\]. Actually, type 2 diabetes and BPH share several common risk factors including aging, insulin resistance and obesity \[[@B3]\]. Studies suggested that type 2 diabetes, obesity and metabolic syndrome may all affect the growth of BPH. For example, an earlier study showed that the annual BPH growth rate for patients without and with type 2 diabetes was 0.928 ml/year and 1.385 ml/year, respectively \[[@B17]\]. The Baltimore Longitudinal Study of Aging suggested that prostate volume increased 0.41 ml with each 1-kg/m^2^ increment of body mass index, and there was a 3.5-fold higher risk of BPH comparing a body mass index of ≥35 kg/m^2^ to that of \<25 kg/m^2^\[[@B14]\]. A study in Turkish men showed that the growth rate of total prostate in BPH patients with and without metabolic syndrome was 1.0 ml/year and 0.64 ml/year, respectively (P = 0.018) \[[@B18]\]. Therefore, the etiology underlying the development of metabolic syndrome including diabetes and obesity may also lead to the growth of prostate.

The number of diabetic patients has been increasing dramatically all over the world in recent decades \[[@B19]\], and this is especially remarkable in the Asian populations \[[@B20]\]. It is estimated that the global number of diabetic patients will increase from 171 million in 2000 to 366 million in 2030; and most of these patients will be seen in Asian countries, with an estimated number of 75 million in 2000 and 180 million in 2030 \[[@B19]\]. Recently, patients with type 2 diabetes have been shown to carry a higher risk of bladder cancer \[[@B21]-[@B24]\] and the use of some anti-diabetic agents (e.g. pioglitazone) might be associated with an increased risk \[[@B25]-[@B28]\]. However, whether BPH can be a risk factor for bladder cancer in the diabetic patients has not been studied. An elucidation of the association between BPH and bladder cancer is not only an issue of scientific interest, it is also important for the planning and implementing programs for the prevention of bladder cancer, either by reducing the incidence of diabetes and BPH or by early treatment of these diseases. Therefore, the purpose of the present study was to evaluate, in men with type 2 diabetes, whether BPH could be a risk factor for bladder cancer.

Methods
=======

Since March 1995 a compulsory and universal system of health insurance (the so-called National Health Insurance, NHI) was implemented in Taiwan. All contracted medical institutes must submit computerized and standard claim documents for reimbursement. More than 99% of citizens are enrolled in the NHI, and \>98% of the hospitals nationwide are under contract with the NHI. The average number of annual physician visits in Taiwan is one of the highest around the world, at approximately 15 visits per year per capita in 2009.

The National Health Research Institute is the only institute approved, as per local regulations, for handling the NHI reimbursement databases for academic research. The databases contain detailed records on every visit for each patient, including outpatient visits, emergency department visits and hospital admission. The databases also include principal and secondary diagnostic codes, prescription orders, and claimed expenses. The identification information of the individuals was scrambled for the protection of privacy. Diabetes was coded 250.1-250.9, BPH 600, and bladder cancer 188, based on the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM).

We first retrieved the databases of all patients who had been diagnosed as having diabetes and under treatment with either oral anti-diabetic agents or insulin during the period of 1996--2009 from the whole nation (*n* = 1789776). The selected entry date was 1 January 2006. After excluding patients who had a diagnosis of diabetes after the year 2006 (*n* = 342351), patients who held a Severe Morbidity Card as having type 1 diabetes (*n* = 7120, in Taiwan, patients with type 1 diabetes were issued a so-called "Severe Morbidity Card" after certified diagnosis and they were waived for much of the co-payments), patients having a diagnosis of bladder cancer before 2006 (*n* = 9555), those who died (*n* = 96320) or withdrew from the NHI (*n* = 12502) before entry date, duplicated identification number (*n* = 106), unclear information on date of birth or sex (*n* = 5122), and diabetic patients without any reimbursement record after the entry date (*n* = 235746), a total of 1094404 patients with a diagnosis of type 2 diabetes and under therapy with oral anti-diabetic agents or insulin were recruited. A further exclusion of the female sex yielded 547584 men with type 2 diabetes for the present study.

All comorbidities and covariates were determined as a status/diagnosis before the entry date. The ICD-9-CM codes for the comorbidities were \[[@B21],[@B29],[@B30]\]: nephropathy 580--589, urinary tract disease 590--599, hypertension 401--405, chronic obstructive pulmonary disease (a surrogate for smoking) 490--496, cerebrovascular disease 430--438, ischemic heart disease 410--414, peripheral arterial disease 250.7, 785.4, 443.81 and 440--448, eye disease 250.5, 362.0, 369, 366.41 and 365.44, dyslipidemia 272.0-272.4, heart failure 398.91, 402.11, 402.91, 404.11, 404.13, 404.91, 404.93 and 428, obesity 278, alcohol-related diagnosis 291, 303, 535.3, 571.0, 571.1, 571.2, 571.3 and 980.0, non-alcohol-related chronic liver disease 570--573, 070 and 571.4 (excluding 571.0, 571.1, 571.2 and 571.3), and cancer other than bladder cancer 140--208 (excluding 188). Medications included rosiglitazone, pioglitazone, sulfonylurea, meglitinide, metformin, acarbose, insulin, statin, fibrate, angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker, calcium channel blocker, non-steroidal anti-inflammatory drugs, alpha-blockers, 5-alpha reductase inhibitors, clopidogrel, ticlopidine, dipyridamole, cyclophosphamide and diuretics. Baseline characteristics between patients with and without BPH were compared by Chi-square test.

The incidence density of bladder cancer was calculated for BPH by status and by duration of BPH diagnosis (\<1 year, 1--3 years, 3--5 years and ≥5 years) in patients of all ages and in patients aged ≥60 years, respectively. Patients with BPH were further categorized into two subgroups: with and without receiving surgical procedures for the treatment of BPH, including transurethral incision of the prostate, transurethral resection of the prostate, suprapubic prostatectomy or retropubic prostatectomy. The numerator for the incidence was the number of patients with incident bladder cancer during the 4-year follow-up from 1 January 2006 until 31 December 2009, and the denominator was the person-years of follow-up.

To compare whether patients with BPH had a higher probability of visits to the urologists or receiving laboratory examinations that might potentially lead to the diagnosis of bladder cancer, the frequencies of these items between patients with and without BPH were analyzed by Chi square test, in all patients and in patients aged ≥60 years, respectively. Laboratory examinations included serum tumor markers (including carcinoembryonic antigen, carbohydrate antigen 19--9, carbohydrate antigen 125 and tissue polypeptide antigen), urine cytology, cystoscopy, urinalysis and bladder ultrasonography. The nuclear matrix protein-22 and the bladder tumor associated antigen tests for screening bladder cancer were not reimbursed by the NHI; and therefore they could not be considered in the analyses.

Cox proportional hazards regression was performed to estimate the hazard ratios for bladder cancer for patients with BPH vs. patients without BPH. The following models were created: 1) BPH vs. no BPH; 2) BPH without surgical procedures, BPH with surgical procedures vs. no BPH; and 3) BPH by duration (\<1 year, 1--3 years, 3--5 years and ≥5 years) vs. no BPH. For sensitivity analyses, the Cox models were also created after excluding patients with surgical procedures and without surgical procedures, respectively, from the analyses. All models were created for all ages and age ≥60 years, respectively. Age, diabetes duration, comorbidities, medications and potential detection examinations were all adjusted for in the models.

To further evaluate the possible effects of diabetes duration and medications used for diabetic control on the risk of bladder cancer among the BPH men, additional Cox regression models were created for the diabetic men with BPH for all ages and for age ≥60 years, respectively. Age, comorbidities, medications other than anti-diabetic drugs and potential detection examinations were all adjusted for in these models.

Analyses were conducted using SAS statistical software, version 9.1 (SAS Institute, Cary, NC). *P* \< 0.05 was considered statistically significant.

Results
=======

Table [1](#T1){ref-type="table"} compares the baseline characteristics between patients with BPH and those without. Patients with BPH were older and had longer diabetes duration, higher rates of comorbidities (except obesity and alcohol-related diagnosis), and higher rates of using medications and other cancer.

###### 

Baseline characteristics by benign prostatic hyperplasia

  **Variables**                                                           **BPH (−)**   **BPH (+)**   ***P value***          
  ---------------------------------------------------------------------- ------------- ------------- --------------- ------- ----------
  *n* = 547584                                                              465485         85.0           82099       15.0        
  Age (years)                                                                                                                     
    \<40                                                                     28373          6.1            103         0.1    \<0.0001
   40-49                                                                     88077         18.9           1692         2.1        
   50-59                                                                    144677         31.1           11014       13.4        
   60-69                                                                    106959         23.0           22785       27.8        
   ≥70                                                                       97399         20.9           46505       56.7        
  Diabetes duration (years)                                                                                                       
   \<1                                                                       43069          9.3           1921         2.3    \<0.0001
   1-3                                                                       83311         17.9           6379         7.8        
   3-5                                                                       7748          16.7           9061        11.0        
   ≥5                                                                       261623         56.2           64738       78.9        
  Nephropathy                                                                53002         11.4           19913       24.3    \<0.0001
  Urinary tract diseases                                                     59012         12.7           33818       41.2    \<0.0001
  Hypertension                                                              248296         53.3           63518       77.4    \<0.0001
  Chronic obstructive pulmonary disease                                      60418         13.0           25837       31.5    \<0.0001
  Cerebrovascular disease                                                    59318         12.7           23756       28.9    \<0.0001
  Ischemic heart disease                                                     95649         20.6           33370       40.7    \<0.0001
  Peripheral arterial disease                                                52064         11.2           18708       22.8    \<0.0001
  Eye disease                                                                75016         16.1           24855       30.3    \<0.0001
  Dyslipidemia                                                              231613         49.8           42928       52.3    \<0.0001
  Heart failure                                                              25584          5.5           11400       13.9    \<0.0001
  Obesity                                                                    6360          1.37            779        0.95    \<0.0001
  Alcohol-related diagnosis                                                  14797         3.18           1885        2.30    \<0.0001
  Non-alcohol-related chronic liver disease                                 155679         33.44          30421       37.05   \<0.0001
  Rosiglitazone                                                              64221         13.8           16898       20.6    \<0.0001
  Pioglitazone                                                               22241          4.8           5191         6.3    \<0.0001
  Sulfonylurea                                                              365375         78.5           74154       90.3    \<0.0001
  Meglitinide                                                                51909         11.2           14783       18.0    \<0.0001
  Metformin                                                                 325652         70.0           69254       84.4    \<0.0001
  Acarbose                                                                   68578         14.7           18395       22.4    \<0.0001
  Insulin                                                                    68122         14.6           20951       25.5    \<0.0001
  Statin                                                                    133169         28.6           26302       32.0    \<0.0001
  Fibrate                                                                   106427         22.9           19705       24.0    \<0.0001
  Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker      198383         42.6           52076       63.4    \<0.0001
  Calcium channel blocker                                                   131769         28.3           40288       49.1    \<0.0001
  Non-steroidal anti-inflammatory drugs                                     303900         65.3           72262       88.0    \<0.0001
  Alpha-blockers                                                             50456         10.84          69086       84.15   \<0.0001
  5-alpha reductase inhibitors                                                425          0.09           3409        4.15    \<0.0001
  Clopidogrel                                                                14395         3.09           5346        6.51    \<0.0001
  Ticlopidine                                                                11315         2.43           5278        6.43    \<0.0001
  Dipyridamole                                                               78550         16.87          30566       37.23   \<0.0001
  Cyclophosphamide                                                            456          0.10            147        0.18    \<0.0001
  Diuretics                                                                 103397         22.21          36462       44.41   \<0.0001
  Other cancer prior to baseline                                             41311          8.9           18433       22.5    \<0.0001

*BPH* benign prostatic hyperplasia.

Table [2](#T2){ref-type="table"} shows the crude incidence of bladder cancer with regards to BPH status or duration. The incidence was 69.34 per 100,000 person-years for patients without BPH and was 258.77 per 100,000 person-years for patients with BPH. For BPH patients, those who underwent a surgical procedure had a higher incidence than those who had not received a surgical procedure (355.45 vs. 250.09 per 100,000 person-years). The incidence seemed to increase with longer duration of BPH and peaked at BPH duration of 3--5 years, especially in those who underwent a surgical procedure. The findings were similar in the analyses for those aged ≥60 years.

###### 

Incidence of bladder cancer with regards to benign prostatic hyperplasia by status or duration with and without surgical procedures

  **BPH status/duration**     **Case number**   ***n*of Incident bladder cancer**   **%**   **Person-years**   **Incidence rate**
  ------------------------- ----------------- ----------------------------------- ------- ------------------ --------------------
  **All ages**                                                                                                                   
  **I. BPH by status**                                                                                                           
   No BPH                              462432                                1127    0.24         1625241.83                69.34
   BPH                                  85152                                 742    0.87          286736.17               258.77
   BPH/procedures (−)                   78526                                 658    0.84          263103.83               250.09
   BPH/procedures (+)                    6626                                  84    1.27           23632.33               355.45
  **II. BPH by duration**                                                                                                        
   All BPH patients                                                                                                              
    \<1 year                            16163                                 126    0.78           54808.83               229.89
    1-3 years                           23955                                 199    0.83           81308.00               244.75
    3-5 years                           20649                                 203    0.98           69799.92               290.83
    ≥5 years                            24385                                 214    0.88           80819.42               264.79
   BPH/procedures (−)                                                                                                            
    \<1 year                            12421                                 107    0.86           41550.17               257.52
    1-3 years                           23005                                 180    0.78           77899.17               231.07
    3-5 years                           19952                                 186    0.93           67255.08               276.56
    ≥5 years                            23148                                 185    0.80           76399.42               242.15
   BPH/procedures (+)                                                                                                            
    \<1 year                             3742                                  19    0.51           13258.67               143.30
    1-3 years                             950                                  19    2.00            3408.83               557.38
    3-5 years                             697                                  17    2.44            2544.83               668.02
    ≥5 years                             1237                                  29    2.34            4420.00               656.11
  **Age ≥60 years**                                                                                                              
  **I. BPH by status**                                                                                                           
   No BPH                              201704                                 779    0.39          685559.17               113.63
   BPH                                  71944                                 684    0.95          238880.17               286.34
   BPH/procedures (−)                   65952                                 605    0.92          217633.42               277.99
   BPH/procedures (+)                    5992                                  79    1.32           21246.75               371.82
  **II. BPH by duration**                                                                                                        
   All BPH patients                                                                                                              
    \<1 year                            12864                                 111    0.86           42903.33               258.72
    1-3 years                           19405                                 182    0.94           64903.08               280.42
    3-5 years                           17536                                 193    1.10           58425.00               330.34
    ≥5 years                            22139                                 198    0.89           72648.75               272.54
   BPH/procedures (−)                                                                                                            
    \<1 year                             9567                                  93    0.97           31307.58               297.05
    1-3 years                           18529                                 164    0.89           61772.17               265.49
    3-5 years                           16885                                 176    1.04           56058.00               313.96
    ≥5 years                            20971                                 172    0.82           68495.67               251.11
   BPH/procedures (+)                                                                                                            
    \<1 year                             3297                                  18    0.55           11595.75               155.23
    1-3 years                             876                                  18    2.05            3130.92               574.91
    3-5 years                             651                                  17    2.61            2367.00               718.21
    ≥5 years                             1168                                  26    2.23            4153.08               626.04

*BPH* benign prostatic hyperplasia, *HR* hazard ratio, *CI* confidence interval.

Table [3](#T3){ref-type="table"} compares the frequency of visits to urologists and laboratory examinations that might potentially lead to the diagnosis of bladder cancer in patients with and without BPH. It is true that patients with BPH had a significantly higher probability of potential detection bias.

###### 

Comparison of the frequency of visits to urologists and laboratory examinations potentially leading to diagnosis of bladder cancer in patients with and without benign prostatic hyperplasia

  **Variables**                **Benign prostatic hyperplasia**   ***P value***                  
  --------------------------- ---------------------------------- --------------- ------- ------- ----------
  **All ages**                                                                                        
  Visits to urologists                                                                                
    No                                      427531                    91.85       59460   72.42   \<0.0001
   Yes                                      37954                     8.15        22639   27.58       
  Laboratory examinations\*                                                                           
   No                                       119766                    25.73       10354   12.61   \<0.0001
   Yes                                      345719                    74.27       71745   87.39       
  Any of the above                                                                                    
   No                                       116896                    25.11       9309    11.34   \<0.0001
   Yes                                      348589                    74.89       72790   88.66       
  **Age ≥60 years**                                                                                   
  Visits to urologists                                                                                
   No                                       185836                    90.94       50441   72.80   \<0.0001
   Yes                                      18522                     9.06        18849   27.20       
  Laboratory examinations\*                                                                           
   No                                       47633                     23.31       8460    12.21   \<0.0001
   Yes                                      156725                    76.69       60830   87.79       
  Any of the above                                                                                    
   No                                       46463                     22.74       7663    11.06   \<0.0001
   Yes                                      157895                    77.26       61627   88.94       

\*Laboratory examinations include serum tumor markers, urine cytology, cystoscopy, urinalysis and bladder ultrasonography.

The hazard ratios with regards to BPH by status or duration are presented in Table [4](#T4){ref-type="table"}. Except for BPH by duration \<1 year in the sensitivity analyses after excluding BPH patients without a surgical procedure from the analyses, all hazard ratios showed a significantly higher risk of bladder cancer associated with BPH. For analyses in all patients of all ages, patients with BPH had a significantly higher risk, with hazard ratio (95% confidence interval): 1.794 (1.572, 2.047). BPH patients with a surgical procedure had a larger magnitude of hazard ratio than those without: 2.459 (1.946, 3.109) vs. 1.709 (1.492, 1.958). The significantly higher risk could be demonstrated in patients with BPH of any duration. The analyses were similar in the sensitivity analyses, but the magnitudes of hazard ratios were larger in patients with a surgical procedure than those without a surgical procedure in any specific BPH duration (except for the category with BPH duration \<1 year).

###### 

Hazard ratios for bladder cancer with regards to benign prostatic hyperplasia

  **BPH**                                         **All ages**   **Age ≥60 years**                                      
  ---------------------------------------------- -------------- ------------------- ---------- ------- ---------------- ----------
  **All patients**                                                                                                           
                                                                    N = 547584                            N = 273648         
  I. BPH by status                                                                                                           
   1. BPH/procedures (−) or (+)                      1.794        (1.572, 2.047)     \<0.0001   1.842   (1.600, 2.121)   \<0.0001
   2. BPH/procedures (−)                             1.709        (1.492, 1.958)     \<0.0001   1.753   (1.517, 2.027)   \<0.0001
    BPH/procedures (+)                               2.459        (1.946, 3.109)     \<0.0001   2.500   (1.960, 3.189)   \<0.0001
  II\. BPH by duration                                                                                                       
    \<1 year                                         1.750        (1.430, 1.605)     \<0.0001   1.769   (1.425, 2.195)   \<0.0001
    1-3 years                                        1.844        (1.543, 2.203)     \<0.0001   1.897   (1.571, 2.291)   \<0.0001
    3-5 years                                        2.011        (1.680, 2.406)     \<0.0001   2.125   (1.760, 2.566)   \<0.0001
    ≥5 years                                         1.605        (1.341, 1.921)     \<0.0001   1.623   (1.343, 1.962)   \<0.0001
  **Sensitivity analyses**                                                                                                   
  **Excluding BPH with surgical procedure**                                                                             
                                                                    N = 540958                            N = 267656         
  I. BPH by status                                   1.740        (1.515, 1.740)     \<0.0001   1.797   (1.549, 2.084)   \<0.0001
  II\. BPH by duration                                                                                                       
    \<1 year                                         1.943        (1.557, 2.425)     \<0.0001   1.975   (1.556, 2.507)   \<0.0001
    1-3 years                                        1.756        (1.459, 2.112)     \<0.0001   1.813   (1.490, 2.207)   \<0.0001
    3-5 years                                        1.913        (1.589, 2.304)     \<0.0001   2.025   (1.666, 2.462)   \<0.0001
    ≥5 years                                         1.474        (1.220, 1.780)     \<0.0001   1.506   (1.233, 1.839)   \<0.0001
  **Excluding BPH without surgical procedure**                                                                          
                                                                    N = 469058                            N = 207696         
  I. BPH by status                                   2.525        (1.984, 3.212)     \<0.0001   2.671   (2.078, 3.433)   \<0.0001
  II\. BPH by duration                                                                                                       
    \<1 year                                         1.200        (0.760, 1.896)      0.4342    1.275   (0.796, 2.041)    0.3123
    1-3 years                                        3.983        (2.477, 6.404)     \<0.0001   4.274   (2.614, 6.988)   \<0.0001
    3-5 years                                        4.648        (2.818, 7.668)     \<0.0001   5.246   (3.163, 8.701)   \<0.0001
    ≥5 years                                         3.837        (2.588, 5.689)     \<0.0001   3.984   (2.621, 6.057)   \<0.0001

*BPH* benign prostatic hyperplasia, *HR* hazard ratio, *CI* confidence interval.

Models are adjusted for all variables in Table [1](#T1){ref-type="table"} and for potential detection examinations in Table [3](#T3){ref-type="table"}.

The referent group in the models is patients without BPH.

Table [5](#T5){ref-type="table"} shows the adjusted hazard ratios for bladder cancer with regards to diabetes duration and medications used for diabetic control in the diabetic men with BPH. It was noted that diabetes duration was not significantly related to bladder cancer in the BPH men; and that among all anti-diabetic drugs only metformin was significantly associated with a lower risk of bladder cancer in the BPH men.

###### 

Hazard ratios for bladder cancer with regards to diabetes duration and medications used for diabetic control in diabetic men with benign prostatic hyperplasia

                                      **All ages**   **Age ≥60 years**                                    
  ---------------------------------- -------------- ------------------- -------- ------- ---------------- --------
  Diabetes duration                                                                                           
    1-3 years vs. \<1 year               0.992        (0.637, 1.546)     0.9731   1.117   (0.680, 1.835)   0.6610
    3-5 years vs. \<1 year               0.735        (0.471, 1.147)     0.1748   0.893   (0.546, 1.461)   0.6534
    ≥5 years vs. \<1 year                0.679        (0.449, 1.027)     0.0664   0.784   (0.494, 1.246)   0.3035
  Medications for diabetic control                                                                            
    Rosiglitazone (Yes vs. No)           1.124        (0.923, 1.369)     0.2443   1.115   (0.908, 1.370)   0.2994
    Pioglitazone (Yes vs. No)            1.023        (0.752, 1.393)     0.8846   1.066   (0.774, 1.467)   0.6959
    Sulfonylurea (Yes vs. No)            0.939        (0.742, 1.190)     0.6035   0.940   (0.734, 1.205)   0.6252
    Meglitinide (Yes vs. No)             1.133        (0.934, 1.375)     0.2057   1.170   (0.958, 1.428)   0.1239
    Metformin (Yes vs. No)               0.719        (0.590, 0.875)     0.0010   0.742   (0.604, 0.912)   0.0046
    Acarbose (Yes vs. No)                1.045        (0.866, 1.261)     0.6471   1.034   (0.850, 1.258)   0.7407
    Insulin (Yes vs. No)                 0.893        (0.738, 1.081)     0.3465   0.880   (0.721, 1.073)   0.2062

*HR* hazard ratio, *CI* confidence interval.

Models are adjusted for all variables in Table [1](#T1){ref-type="table"} and for potential detection examinations in Table [3](#T3){ref-type="table"}.

Discussion
==========

The present study strongly suggested that BPH is an important risk factor for bladder cancer in patients with type 2 diabetes (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}). Furthermore, BPH patients who had received a surgical procedure might have a higher magnitude of hazard ratio than those without a surgical procedure (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}), suggesting that patients with more severe clinical conditions of BPH might have a higher risk of bladder cancer. Although BPH patients were older, had higher prevalences of most comorbidities and medications used (Table [1](#T1){ref-type="table"}) and a higher probability of detection bias (Table [3](#T3){ref-type="table"}), the risk associated with BPH could not be ascribed to these confounders (Table [4](#T4){ref-type="table"}). The effect of BPH on bladder cancer risk seemed to be independent of diabetes because none of the diabetes duration was significantly related with bladder cancer in the BPH men (Table [5](#T5){ref-type="table"}). It was also observed that, in the BPH men, those who used metformin might have a significantly lower risk of bladder cancer than those who had never used metformin (Table [5](#T5){ref-type="table"}), suggesting a potentially preventive effect of metformin against bladder cancer development.

A possible explanation for a link between BPH and bladder cancer is that the residual urine in the bladder in patients with BPH may increase the time of urothelial exposure to urinary excreted carcinogens. Such a hypothesis is strongly supported by the animal study by Matsumoto et al. because bladder cancer induced by the carcinogen n-butyl-n-butanol nitrosamine may also be aggravated by surgically induced bladder outlet obstruction in female Wistar rats \[[@B4]\]. Another circumstantial evidence supporting the hypothesis in humans came from prospective \[[@B31]\] and case--control \[[@B32]\] studies showing that high fluid intake, indicating less concentrated urine or more frequent micturition, was associated with a lower risk of bladder cancer.

Patients with BPH also have a significantly higher risk of chronic kidney disease, probably due to an obstructive uropathy \[[@B33]\]. Chronic kidney disease has been consistently proved to be a significant risk factor for bladder cancer in the Taiwanese population \[[@B21],[@B34]\]. Therefore, the increased risk of bladder cancer in patients with BPH could also be partially explained by the higher incidence of chronic kidney disease in these patients.

In the Swedish prospective follow-up study, there was a lack of an overall risk of bladder cancer associated with BPH \[[@B7]\], in contrary to a significant association in the present study (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}). There were several possible explanations. First, the Swedish study used the bladder cancer incidence in the general population as referents for the calculation of the standardized incidence ratio. The referent groups would surely include the BPH patients in the study and also include other high risk patients like the diabetic patients who may have an increased risk of bladder cancer \[[@B21]-[@B24]\]. Second, the Swedish study could not consider the adjustment for potential confounders except for age. Furthermore, different ethnicities might also be a possible explanation. It should be pointed out that the Swedish study did show a significantly 2-fold higher risk of bladder cancer in a subgroup of the BPH men who underwent transurethral resection of the prostate and had genitourinary conditions such as urinary tract infection and stones \[[@B7]\]. This was consistent with the findings of the present study (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}), and with our previous study showing a significantly higher risk of bladder cancer in patients with a history of urinary tract infection or stones \[[@B21]\].

Although the etiology of BPH remains unknown, metabolic disturbances may promote the growth of prostate. Obesity, insulin resistance with elevated insulin level, and higher serum concentration of insulin-like growth factor-I are associated with a significantly higher risk of BPH \[[@B3],[@B35],[@B36]\]. Obesity and diabetes are also associated with systemic inflammation and oxidative stress, which may promote the inflammatory processes in the prostate, leading to clinical development of BPH \[[@B3]\]. The link between BPH and some lifestyle risk factors of type 2 diabetes such as physical inactivity and dietary factors including increased total energy intake and less vegetables or vitamin D \[[@B3],[@B15]\] also strongly support the existence of some common underlying etiology for BPH and type 2 diabetes, which may well explain the observed association between BPH and type 2 diabetes.

Diabetic patients have an increased risk of bladder cancer \[[@B21]-[@B24]\]. The etiology for such a link has not yet been clarified. Some possible mechanisms have been proposed based on elevated blood glucose, insulin resistance, elevated levels of insulin and insulin-like growth factor-I, higher prevalences of neurogenic bladder and sympathetic nerve dysfunction in the diabetic patients \[[@B12]\]. Some recent studies also suggested a possible higher risk of bladder cancer associated with the use of pioglitazone in patients with type 2 diabetes \[[@B25]-[@B28]\]. The present study suggested another possible mechanism, which acts through BPH in the diabetic patients.

There are several important clinical implications from the present study. First, BPH-related bladder cancer can be preventable if BPH is prevented or adequately treated at its early stage. Second, in diabetic men with BPH, the use of metformin is potentially preventive for the development of bladder cancer. This finding surely provides a good rationale for the conduction of clinical trials evaluating the use of metformin for the prevention of bladder cancer among high-risk patients with BPH. Third, type 2 diabetes is increasing more remarkably in men than in women in the Taiwanese younger generation in recent 2 decades, probably due to the increasing epidemic of obesity in the young men \[[@B37],[@B38]\]. It is expected that the incidence of bladder cancer in the male population will be increasing in the future when these young and obese diabetic patients become older, because of the link between diabetes and BPH and the higher risk of bladder cancer related to BPH as shown in the present study. Therefore lifestyle modification to reduce the incidence of obesity, diabetes and metabolic syndrome is mandatory not only for preventing the development of BPH, but also for reducing the incidence of bladder cancer. Fourth, the potential confounding effect of BPH should not be neglected while evaluating the association between some medications and bladder cancer risk. For examples, most recent studies evaluating the risk of bladder cancer related to pioglitazone have not seriously considered such a potential confounding from BPH and therefore their conclusion of a positive link could be challenged with a lack of such an adjustment for BPH. Furthermore, an increased risk of bladder cancer has been warned for a new class of oral anti-diabetic agents being under consideration for approval for human use, i.e., the sodium-dependent glucose cotransporter 2 inhibitors with a novel mechanism of inhibiting glucose reabsorption from the kidney \[[@B39]\]. It is strongly suggested that the potential confounding effect of BPH on bladder cancer risk should be assessed during the evaluation for its approval.

Because all diabetic patients were treated with oral anti-diabetic medications or insulin at entry, the chance of misclassification of diabetes was actually very low. However, we could not exclude the possibility of misclassification of bladder cancer and BPH. The probability of misclassification of bladder cancer must be low, because labeled diagnoses should be printed out in all prescriptions handed to the patients. Mislabeling of a cancer diagnosis would not be acceptable to the patients when they saw the diagnosis. With regards to the misclassification of BPH, this might not occur in patients who had received a surgical procedure. Our analyses in different subgroups of the BPH patients (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}) did not favor a possible impact resulting from such a misclassification. It should be stressed that underdiagnosis of BPH was possible, especially when it was in the early stage without remarkable symptoms. However, if BPH increased the risk of bladder cancer, a misclassification of patients with BPH in the referent group would only have underestimated the hazard ratios.

Because the databases were derived from the whole population and they spanned the whole period from the beginning of the NHI to the end of 2009, there was no concern of potential selection bias related to sampling error. The longitudinal nature of the study and the use of medical records reduced the likelihood of reverse causality and recall bias. However, it should also be mentioned that the local law restricts to retrieve only a certain percentage of the reimbursement data from the whole NHI databases for academic research. Therefore, it was not possible for the present study to include the detailed information on surgical procedures for bladder cancer and additional data from non-diabetic general population for more in-depth analyses on the use of total cystectomy as a surrogate for "invasive bladder cancer" and for a comparison of bladder cancer risk associated with BPH in non-diabetic Taiwanese men, respectively.

Smoking is an important risk factor for bladder cancer \[[@B40]\], but we did not have information of smoking for adjustment and could only consider surrogates that are highly related to smoking, such as chronic obstructive pulmonary disease, ischemic heart disease, cerebrovascular disease and peripheral arterial disease (Table [4](#T4){ref-type="table"}). Theoretically, a confounder should be correlated simultaneously with both the exposure (BPH) and the outcome (bladder cancer), and it should not be an intermediate between exposure and outcome \[[@B41]\]. There is no evidence showing smoking as a determinant for BPH \[[@B2],[@B15],[@B16]\].

This study has several strengths. The databases included all claim records on outpatient visits, emergency department visits and hospital admission, and we caught the diagnoses from all sources. Cancer is considered a severe morbidity by the NHI and most medical co-payments can be waived. Furthermore, there is a low drug cost-sharing required by the NHI and patients with certain conditions such as low-income household, veterans or patients with prescription refills for chronic disease are exempted from the drug cost-sharing \[[@B42]\]. Therefore the detection rate of bladder cancer would not tend to differ among different social classes.

The study limitations included a lack of actual measurement data for confounders such as obesity, smoking, alcohol drinking, water intake, family history, lifestyle, diet, hair dye use, and some occupational exposure and genetic parameters. In addition, we did not have biochemical data for evaluating their impact. Another limitation is the lack of information on the grading and staging of bladder cancer.

Conclusions
===========

This population-based cohort study in Taiwan suggests that BPH is a significant risk factor for bladder cancer in men with type 2 diabetes. Metformin may protect against bladder cancer in the BPH men. This commonly seen risk factor of BPH should not be neglected in future studies evaluating bladder cancer risk.
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